Literature DB >> 33420388

Are we ready for post-transplant cyclophosphamide use in matched donor transplants?

Leonid Volodin1.   

Abstract

Entities:  

Year:  2021        PMID： 33420388     DOI： 10.1038/s41409-020-01204-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

2.  Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching.

Authors:  Chiara Oltolini; Raffaella Greco; Laura Galli; Daniela Clerici; Francesca Lorentino; Elisabetta Xue; Maria Teresa Lupo Stanghellini; Fabio Giglio; Lina Uhr; Marco Ripa; Paolo Scarpellini; Massimo Bernardi; Consuelo Corti; Jacopo Peccatori; Antonella Castagna; Fabio Ciceri
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-28       Impact factor: 5.742

3.  Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation.

Authors:  Raffaella Greco; Francesca Lorentino; Mara Morelli; Fabio Giglio; Daniele Mannina; Andrea Assanelli; Sara Mastaglio; Serena Dalto; Tommaso Perini; Lorenzo Lazzari; Simona Piemontese; Consuelo Corti; Magda Marcatti; Massimo Bernardi; Maria Teresa Lupo Stanghellini; Fabio Ciceri; Jacopo Peccatori
Journal:  Blood       Date:  2016-08-05       Impact factor: 22.113

4.  Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Authors:  Javier Bolaños-Meade; Ran Reshef; Raphael Fraser; Mingwei Fei; Sunil Abhyankar; Zaid Al-Kadhimi; Amin M Alousi; Joseph H Antin; Sally Arai; Kate Bickett; Yi-Bin Chen; Lloyd E Damon; Yvonne A Efebera; Nancy L Geller; Sergio A Giralt; Parameswaran Hari; Shernan G Holtan; Mary M Horowitz; David A Jacobsohn; Richard J Jones; Jane L Liesveld; Brent R Logan; Margaret L MacMillan; Marco Mielcarek; Pierre Noel; Joseph Pidala; David L Porter; Iskra Pusic; Ronald Sobecks; Scott R Solomon; Daniel J Weisdorf; Juan Wu; Marcelo C Pasquini; John Koreth
Journal:  Lancet Haematol       Date:  2019-03       Impact factor: 18.959

5.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

6.  Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

Authors:  Eolia Brissot; Myriam Labopin; Ian Moiseev; J J Cornelissen; Ellen Meijer; Gwendolyn Van Gorkom; Montserrat Rovira; Fabio Ciceri; Laimonas Griskevicius; Didier Blaise; Edouard Forcade; Martin Mistrik; Stephan Mielke; Claude Eric Bulabois; Riitta Niittyvuopio; Eric Deconinck; Annalisa Ruggeri; Jaime Sanz; Alexandros Spyridonidis; Bipin Savani; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  J Hematol Oncol       Date:  2020-07-03       Impact factor: 17.388

Review 7.  Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.

Authors:  Louis Williams; Frank Cirrone; Kelli Cole; Maher Abdul-Hay; Leo Luznik; Ahmad Samer Al-Homsi
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.